With a satisfying year of revenues from Ampyra (dalfampridine) under its belt, Acorda Therapeutics Inc. has declared readiness to take on not only challenges from generic drugmakers but, most recently, an inter partes review (IPR) petition by hedge fund manager Kyle Bass. Read More
SHANGHAI – Hua Medicine Ltd.'s sinogliatin, a fourth-generation glucokinase activator (GKA), looks set to prove it has overcome the issues of past GKA's to provide 24-hour glucose control in diabetics with the potential to improve pancreatic beta cell function. Read More
As antibiotic resistance grows, it is increasingly recognized as not just a public health issue. Drug-resistant bacteria, like viruses with pandemic potential, have the capacity to overwhelm health care systems and cause broader social disruption. Even now, without such social disruption, their overall impact is shocking. Read More
Smart medicine may or may not be on the near horizon, but speakers at a National Institutes of Health- (NIH) sponsored meeting on the president's Precision Medicine Initiative are bullish on the prospects for this new paradigm of health and medical care, even if they see a few sizeable hurdles. Read More
HONG KONG – South Korea's Ministry of Food and Drug Safety (MFDS) has approved the country's first tissue-specific osteoarthritis drug, which its manufacturer hopes will soon grab 10 percent of the Korean arthritis market. Read More
Incyte Corp., of Wilmington, Del., reported net product revenues of Jakafi (ruxolitinib) were $106 million for the quarter ended Dec. 31, 2014, as compared to $73 million for the same period in 2013. Read More
Harvard Apparatus Regenerative Technology Inc., of Holliston, Mass., said it is proposing, in an underwritten public offering, to offer shares of its common stock and series B convertible preferred stock. At the option of the investor, the series B stock is convertible into five shares of common stock. Read More
Elusys Therapeutics Inc., of Pine Brook, N.J., said obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severities in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis. Read More
Aileron Therapeutics Inc., of Cambridge, Mass., dosed the first patients in a phase I trial of ALRN-6924, a potent and specific re-activator of the tumor suppressor protein known as wild type p53. ALRN-6924 binds equipotently and inhibits both of the p53 suppressor proteins, MDM2 and MDMX. Read More
Raritan, N.J.-based Janssen Research & Development LLC, part of Johnson & Johnson, launched three new research platforms focused on disease prevention, disease interception and the microbiome – areas of transformational medical innovation that are expected to change the health care landscape. Read More
Pfizer Inc., of New York, said researchers presented new data for Elelyso (taliglucerase alfa) for injection to treat pediatric patients with type 1 Gaucher disease at the 11th Annual World Symposium in Orlando, Fla., including findings from a multicenter, phase III extension trial evaluating the long-term efficacy and safety of Elelyso in patients who were treatment-naïve or previously treated with imiglucerase. Read More
